STAT3 and brain neoplasm: Studies targeting OSMRβ and STAT3 suggest that a clinical therapeutic that disrupts OSM/OSMRβ/STAT3 signaling can repress brain tumor growth and increase chemoresistance in aggressive brain tumors (183, 249).